Drug-induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor

Drug induced agranulocytosis (DIA) is a potentially lethal disorder characterized by selective neutropenia. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been utilized for its treatment. We report four cases of DIA treated with GM-CSF at the dose of 5 micrograms/kg/day. The patients...

Full description

Saved in:
Bibliographic Details
Published inRevista de investigacion clinica Vol. 46; no. 1; pp. 59 - 61
Main Authors HURTADO M, R, CANDELARIA-H, M, MAJLUF-CRUZ, A, SOSA-CAMAS, R. E, LABARDINI-MENDEZ, J
Format Journal Article
LanguageEnglish
Published México Hospital de Enfermedades de la Nutricíon 1994
Subjects
Adult
Aged
Agranulocytosis - chemically induced
Agranulocytosis - therapy
Anti-Bacterial Agents - adverse effects
Biological and medical sciences
Drug toxicity and drugs side effects treatment
Female
Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use
Graves Disease - complications
Graves Disease - drug therapy
Humans
Immunologic Factors - therapeutic use
Leukocyte Count
Male
Medical sciences
Methimazole - adverse effects
Neutrophils
Pharmacology. Drug treatments
Tonsillitis - complications
Tonsillitis - drug therapy
Toxicity: blood
Tropical medicine
Human
Leukopenia
Reticuloendothelial system
Toxicity
Agranulocytosis
Treatment efficiency
Cytokine
Hemopathy
Blood
Chemotherapy
Treatment
Polypeptide
Granulocyte macrophage colony stimulating factor
Neutropenia
Online AccessGet full text

Cover

More Information
Summary:Drug induced agranulocytosis (DIA) is a potentially lethal disorder characterized by selective neutropenia. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been utilized for its treatment. We report four cases of DIA treated with GM-CSF at the dose of 5 micrograms/kg/day. The patients presented infectious diseases at diagnosis. Median days to obtain 1 x 10(9)/L neutrophils and a normal neutrophil count (NNC), were 7(5-9) and 7.5 (6-10) days, respectively. The infectious disease at diagnosis improved and all patients are alive at the moment of this report. No other adverse effects than thrombocytosis (two cases) and thrombocytopenia (one case) were observed. We consider that GM-CSF could be a safe and effective alternative in the treatment of DIA.
ISSN:0034-8376